Reserach Advances on Nanozyme-Guided Therapy of Inflammatory Bowel Diseases<sup>★</sup>

Chen, Qiwen; Zhang, Xianzheng

doi:10.6023/a23040144

Cited by 2 publications

(1 citation statement)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, many nanoenzymes with anti-inflammatory properties mimic these natural enzymes. 130 According to a recent study, Ni3S4 was determined to be the most effective material, which displays dual enzyme-like activity for POD and SOD. Yu et al 119 designed and developed a novel oral nano-enzymatic therapeutic system that targeted the release of anti-inflammatory enzymes in a cascade reaction to enable efficient treatment of IBD.…”

Section: Enzyme Responsivenessmentioning

confidence: 99%

Nanodrug delivery materials for digestive system diseases

Yang,

Zeng,

Zhuang

et al. 2024

APL Materials

View full text Add to dashboard Cite

Digestive system diseases, such as gastritis, gastric ulcers, chronic liver disease, inflammatory bowel disease (IBD), and colorectal cancer, represent a major group of diseases that have high morbidity and death rates worldwide. Their incidence continues to rise owing to factors such as dietary structure changes, accelerated lifestyles, increased environmental pollution, and population aging. Despite the rapid development of the medical technology, the treatment of digestive diseases still faces many challenges, such as addressing drug-resistant Helicobacter pylori infections, treating IBD, and improving the efficacy of advanced gastrointestinal tumor therapies. Fortunately, the emergence of drug-releasing materials has provided new insights that can be used in the treatment of digestive disorders. Drug-releasing materials are a category of specially designed carriers or systems capable of carrying drugs and controlling their release at specific time intervals on demand to achieve the desired therapeutic effect. This article reviews recent research progress of drug-releasing materials used to diagnose and treat digestive disorders. First, the limitations of traditional oral drug delivery methods, such as low bioavailability and nonspecific distribution, are discussed. Second, different types of drug-releasing materials, such as liposomes, dendritic polymers, micelles, nanogels, inorganic nanoparticles, and extracellular vesicles, along with their advantages in terms of improved drug stability, biocompatibility, targeting, and controlled release, are outlined. In addition, the application strategies and preclinical findings of various drug release materials for different digestive disorders are discussed in detail. This Review could help researchers explore more advanced nanomaterials for personalized treatment of drug delivery for digestive disorders.

show abstract

Section: Enzyme Responsivenessmentioning

confidence: 99%

Nanodrug delivery materials for digestive system diseases

Yang,

Zeng,

Zhuang

et al. 2024

APL Materials

View full text Add to dashboard Cite

show abstract

Sulfasalazine‐Loaded Copper‐Tannic Acid Coordination Nanozyme Enables ROS Scavenging and Immunomodulation for Inflammatory Bowel Disease Therapy

Yan,

Liang,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is associated with elevated levels of reactive oxygen species (ROS) and an increased expression of proinflammatory cytokines. Anti‐inflammatory drugs, monoclonal antibodies, and immunomodulators are commonly employed to control the inflammatory response in the management of IBD. Here, a copper and tannic acid (TA) coordination nanozyme (CuTA) loaded with sulfasalazine (SSZ‐CuTA) is synthesized for the treatment of IBD by simultaneous scavenging ROS and immunosuppression. The CuTA exhibits both dismutase‐like activity and catalase‐like activity, making it efficient at scavenging ROS. These nanozymes can efficiently traverse gastric acid and subsequently exert their effects within the intestinal tract. It is verified that SSZ‐CuTA can restore intestinal mucosal and goblet cells to a healthy state by effectively eliminating ROS and reducing the pro‐inflammatory factors in a mouse IBD model. Overall, the SSZ‐CuTA will offer a promising alternative treatment for patients suffering from IBD where excessive ROS and high inflammation coexist.

show abstract

Reserach Advances on Nanozyme-Guided Therapy of Inflammatory Bowel Diseases^★

Cited by 2 publications

References 122 publications

Nanodrug delivery materials for digestive system diseases

Nanodrug delivery materials for digestive system diseases

Sulfasalazine‐Loaded Copper‐Tannic Acid Coordination Nanozyme Enables ROS Scavenging and Immunomodulation for Inflammatory Bowel Disease Therapy

Contact Info

Product

Resources

About

Reserach Advances on Nanozyme-Guided Therapy of Inflammatory Bowel Diseases★

Cited by 2 publications

References 122 publications

Nanodrug delivery materials for digestive system diseases

Nanodrug delivery materials for digestive system diseases

Sulfasalazine‐Loaded Copper‐Tannic Acid Coordination Nanozyme Enables ROS Scavenging and Immunomodulation for Inflammatory Bowel Disease Therapy

Contact Info

Product

Resources

About

Reserach Advances on Nanozyme-Guided Therapy of Inflammatory Bowel Diseases^★